- Chevron Corp (CVX) Reports Profit of $201 million in third quarter 2020
- IBM Enters Esports Arena with Activision Blizzard in New Multi-Year Deal as the Presenting Partner of the Overwatch League Grand Finals
- U.S. General Services Administration (GSA) Deploys BIO-key’s PortalGuard Identity and Access Management (IAM) Solution for Two-factor Authentication Compliance
- J Jill Declares Transaction Support Agreement (TSA) to consolidate its Balance Sheet and Position the Company for Long-Term Growth
- SUI Feasibility research in Viveve Medical, Inc. (NASDAQ:VIVE) showed Positive efficacy data and Preclinical outcomes that favor the Viveve’s New Sham Tip for Critical PURSUIT Trial
On Wednesday, total volume of the DarioHealth Corp. (NASDAQ:DRIO) was 13.68K shares during the trading session, while its average volume is 140.10K shares. The firm remained among day gainers, opened at the price of $6.19, whereas its closing price was recorded at $6.27. It surged 4.50% and traded within the range of $5.82 – $6.32 for the day. The 52-week range of the stock remained in between $3.44 – $18.60. The company’s total market capitalization stands at $14.55 million, along with 2.32 million outstanding shares.
DarioHealth Corp. (DRIO) on January 9, 2020 proclaimed the arrangement of Richard Anderson as its President and General Manager of North America, viable January 13, 2020. Answering to Chief Executive Officer Erez Raphael, Mr. Anderson will be responsible for both operational and business advancement, concentrating essentially on the U.S. showcase. His choice denotes a key intonation point, supporting DarioHealth’s vital activities in the business-to-business (B2B) channel. This is one of numerous authoritative changes that underscore our attention on this enormous market. Related to Mr. Anderson’s arrangement, DarioHealth will change Olivier Jarry to fill in as Senior Vice President of Strategy and Business Development.
“I am eager to join DarioHealth, which has built up itself as an innovator in the advanced wellbeing market during this time of touchy development,” said Mr. Anderson. “I was pulled in to working with DarioHealth given its interesting abilities in conveying financially savvy customized proof based, computerized helpful intercessions over the constant condition range. With a stage that drives high client commitment and clinical viability, DarioHealth is very much situated to bring down human services costs over the framework. I trust in DarioHealth’s capacity to drive an incentive by giving payers, suppliers, and buyers the apparatuses, innovation, information investigation and bolster expected to oversee constant conditions each day. I anticipate working nearby DarioHealth’s authority group and expanding on these activities to drive future development.”
Richard Anderson comes to DarioHealth from Catasys, Inc., where he went through more than 10 years developing its business. He at last filled in as President, Chief Operating Officer and was an individual from its directorate. In his job, Richard constructed and scaled a business that created a huge number of dollars in repeating income. Under Richard’s authority, Catasys consented to arrangements with a couple of the biggest wellbeing plans in the U.S. Before Catasys, from 2005-2008, he was a Senior Executive Vice President of Hythiam, Inc., an antecedent organization of Catasys, Inc. He additionally recently filled in as Chief Financial Officer and Secretary of Clearant, Inc., a biotechnology organization from 1999 to 2005. Preceding Clearant, from 1999-2001, he was the Chief Financial Officer and Managing Director of Intellect Capital Group, an endeavor counseling firm.
The moving average for last 20 days of DarioHealth is at -2.22%, while the average went 6.31 by -24.46% during the last 50 days with -31.22% recorded during the last 200 days. Furthermore, this stock’s distance from its 52-week high price is currently down by -66.29%, while it’s sitting 82.27% away from its 52-week low price.